Current treatment options in RAS mutant metastatic colorectal cancer patients: a meta-analysis of 14 randomized phase III trials.
Angiogenic
Chemotherapy
Colorectal cancer
Metastatic
RAS
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
22
05
2020
accepted:
10
06
2020
pubmed:
21
6
2020
medline:
14
7
2020
entrez:
21
6
2020
Statut:
ppublish
Résumé
Although biomarkers for patients with metastatic colorectal cancer exist, the benefit patients with RAS mutated tumors derive from established regimens is unclear. Efficacy of therapeutic strategies available for RAS mutated patients (addition of chemotherapeutic agents and/or anti angiogenic agents) were investigated in fourteen randomized controlled phase III trials at trial level by meta-analysing individual study hazard ratios and 95% confidence intervals (95% CI) for overall survival (OS) and progression free survival (PFS). 6810 of 10,748 patients (63.3%) were available (48.5% RAS wildtype, 51.5% RAS mutated). Across all treatment lines, additional treatment efficacy (chemotherapy and/or anti angiogenic agents) was significantly smaller in RAS mutated compared to wildtype tumors for OS and PFS. In detail, patients with RAS mutated metastatic colorectal cancer derived significant benefit in PFS but not in OS by the addition of either chemotherapy or anti angiogenic agents to the respective comparator. In patients with RAS wildtype metastatic colorectal cancer, PFS and OS were improved by the addition of chemotherapy or anti angiogenic agent. The therapeutic benefit of additional substances is less distinct in patients with RAS mutated as compared to RAS wildtype metastatic colorectal cancer, especially with regard to OS.
Identifiants
pubmed: 32561975
doi: 10.1007/s00432-020-03290-y
pii: 10.1007/s00432-020-03290-y
pmc: PMC7324435
doi:
Substances chimiques
Angiogenesis Inhibitors
0
ras Proteins
EC 3.6.5.2
Types de publication
Journal Article
Meta-Analysis
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2077-2087Références
Andreyev HJ, Norman AR, Cunningham D, Oates JR, Clarke PA (1998) Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. J Natl Cancer Inst 90:675–684
doi: 10.1093/jnci/90.9.675
Andreyev HJ et al (2001) Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study. Br J Cancer 85:692–696. https://doi.org/10.1054/bjoc.2001.1964
doi: 10.1054/bjoc.2001.1964
pubmed: 11531254
pmcid: 2364126
Aparicio T et al (2018) Bevacizumab maintenance versus no maintenance during chemotherapy-free intervals in metastatic colorectal cancer: a randomized phase III trial (PRODIGE 9). J Clin Oncol 36:674–681. https://doi.org/10.1200/JCO.2017.75.2931
doi: 10.1200/JCO.2017.75.2931
pubmed: 29346040
Baraniskin A, Buchberger B, Pox C, Graeven U, Holch JW, Schmiegel W, Heinemann V (2019) Efficacy of bevacizumab in first-line treatment of metastatic colorectal cancer: a systematic review and meta-analysis. Eur J Cancer 106:37–44. https://doi.org/10.1016/j.ejca.2018.10.009
doi: 10.1016/j.ejca.2018.10.009
pubmed: 30476731
Barault L et al (2008) Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers. Int J Cancer 122:2255–2259. https://doi.org/10.1002/ijc.23388
doi: 10.1002/ijc.23388
pubmed: 18224685
Benvenuti S et al (2007) Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 67:2643–2648. https://doi.org/10.1158/0008-5472.CAN-06-4158
doi: 10.1158/0008-5472.CAN-06-4158
pubmed: 17363584
Cremolini C et al (2015) FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol 16:1306–1315. https://doi.org/10.1016/S1470-2045(15)00122-9
doi: 10.1016/S1470-2045(15)00122-9
pubmed: 26338525
Cunningham D et al (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337–345. https://doi.org/10.1056/NEJMoa033025
doi: 10.1056/NEJMoa033025
pubmed: 15269313
Douillard JY et al (2013) Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 369:1023–1034. https://doi.org/10.1056/NEJMoa1305275
doi: 10.1056/NEJMoa1305275
pubmed: 24024839
Goey KKH et al (2017) Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: updated results and molecular subgroup analyses of the phase 3 CAIRO3 study. Ann Oncol 28:2128–2134. https://doi.org/10.1093/annonc/mdx322
doi: 10.1093/annonc/mdx322
pubmed: 28911067
Grothey A et al (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:303–312. https://doi.org/10.1016/S0140-6736(12)61900-X12657
doi: 10.1016/S0140-6736(12)61900-X12657
pubmed: 23177514
Hegewisch-Becker S et al (2015) Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncol 16:1355–1369. https://doi.org/10.1016/S1470-2045(15)00042-X
doi: 10.1016/S1470-2045(15)00042-X
pubmed: 26361971
Hegewisch-Becker S et al (2018) Impact of primary tumour location and RAS/BRAF mutational status in metastatic colorectal cancer treated with first-line regimens containing oxaliplatin and bevacizumab: Prognostic factors from the AIO KRK0207 first-line and maintenance therapy trial. Eur J Cancer 101:105–113. https://doi.org/10.1016/j.ejca.2018.06.015
doi: 10.1016/j.ejca.2018.06.015
pubmed: 30036739
Heinemann V et al (2014) FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 15:1065–1075. https://doi.org/10.1016/S1470-2045(14)70330-4
doi: 10.1016/S1470-2045(14)70330-4
pubmed: 25088940
Hurwitz HI, Yi J, Ince W, Novotny WF, Rosen O (2009) The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer. Oncologist 14:22–28. https://doi.org/10.1634/theoncologist.2008-0213
doi: 10.1634/theoncologist.2008-0213
pubmed: 19144677
Jonker DJ et al (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357:2040–2048. https://doi.org/10.1056/NEJMoa071834
doi: 10.1056/NEJMoa071834
pubmed: 18003960
Kubicka S et al (2013) Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings. Ann Oncol 24:2342–2349. https://doi.org/10.1093/annonc/mdt231
doi: 10.1093/annonc/mdt231
pubmed: 23852309
Li J et al (2015) Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial Lancet. Oncol 16:619–629. https://doi.org/10.1016/S1470-2045(15)70156-7
doi: 10.1016/S1470-2045(15)70156-7
Mehta VB, Besner GE (2007) HB-EGF promotes angiogenesis in endothelial cells via PI3-kinase and MAPK signaling pathways. Growth Factors 25:253–263. https://doi.org/10.1080/08977190701773070
doi: 10.1080/08977190701773070
pubmed: 18092233
Modest DP et al (2016) Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group. Ann Oncol 27:1746–1753. https://doi.org/10.1093/annonc/mdw261
doi: 10.1093/annonc/mdw261
pubmed: 27358379
pmcid: 4999563
Modest DP et al (2018) Sequential versus combination therapy of metastatic colorectal cancer using fluoropyrimidines, irinotecan, and bevacizumab: a randomized, controlled study-XELAVIRI (AIO KRK0110). J Clin Oncol. https://doi.org/10.1200/JCO.18.00052
doi: 10.1200/JCO.18.00052
pubmed: 30388045
Obermannova R et al (2016) Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression. Ann Oncol 27:2082–2090. https://doi.org/10.1093/annonc/mdw402
doi: 10.1093/annonc/mdw402
pubmed: 27573561
pmcid: 5091322
Price TJ et al (2015) Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer. Br J Cancer 112:963–970. https://doi.org/10.1038/bjc.2015.37
doi: 10.1038/bjc.2015.37
pubmed: 25742472
pmcid: 4366893
Richman SD et al (2009) KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol 27:5931–5937. https://doi.org/10.1200/JCO.2009.22.4295
doi: 10.1200/JCO.2009.22.4295
pubmed: 19884549
Sobrero AF et al (2008) EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 26:2311–2319. https://doi.org/10.1200/JCO.2007.13.1193
doi: 10.1200/JCO.2007.13.1193
pubmed: 18390971
Van Cutsem E et al (2016) ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 27:1386–1422. https://doi.org/10.1093/annonc/mdw235
doi: 10.1093/annonc/mdw235
pubmed: 27380959
Van Cutsem E et al (2018) The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer. Eur J Cancer 90:63–72. https://doi.org/10.1016/j.ejca.2017.10.009
doi: 10.1016/j.ejca.2017.10.009
pubmed: 29274618
Vogelstein B et al (1988) Genetic alterations during colorectal-tumor development. N Engl J Med 319:525–532. https://doi.org/10.1056/NEJM198809013190901
doi: 10.1056/NEJM198809013190901
pubmed: 2841597
Wirapati P et al (2017) Velour trial biomarkers update: Impact of RAS, BRAF, and sidedness on aflibercept activity. J Clin Oncol 35:3538–3538. https://doi.org/10.1200/JCO.2017.35.15_suppl.3538
doi: 10.1200/JCO.2017.35.15_suppl.3538